DBV Technologies (FRA:DBV1) Change In Receivables : €0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Change In Receivables?

DBV Technologies's change in receivables for the quarter that ended in Mar. 2025 was €0.00 Mil. It means DBV Technologies's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

DBV Technologies's change in receivables for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means DBV Technologies's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

DBV Technologies's Accounts Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. DBV Technologies's liquidation value for the three months ended in Mar. 2025 was €-32.12 Mil.

DBV Technologies Change In Receivables Historical Data

The historical data trend for DBV Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Change In Receivables Chart

DBV Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-1.70

1.90

DBV Technologies Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

DBV Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

DBV Technologies (FRA:DBV1) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

DBV Technologies's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, DBV Technologies's accounts receivable are only considered to be worth 75% of book value:

DBV Technologies's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.99	-	44.112	+	0.75 * 0	+	0.5 * 0
=	-32.12

DBV Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (FRA:DBV1) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

DBVT:USA 0QAJ:UK DBV:France DBV:Germany

Address

107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320

Website

https://www.dbv-technologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

DBV Technologies Headlines

No Headlines